Recently, the National Health Insurance Administration issued a notice to issue the “Model Medical Insurance Service Agreement for Designated Medical Institutions” and “Model Medical Insurance Service Agreement for Designated Retail Pharmacies”, which provide basic guidelines for all co-ordinated regions of the country to draw up new medical insurance service agreement texts. The 2026 model agreement further revised and perfected the 2024 model agreement, formulated and issued a negative list of agreement management, refined the specific circumstances, forms, and basis for handling the violations and violations of the agreement by designated medical institutions, clearly delineated the “bottom line” of the designated medical institutions' compliance with the law and regulations, and further strictly regulated management. At the same time, the 2026 model agreement emphasizes the principle of voluntary and equal consultation, empowers the development of designated pharmaceutical institutions, and helps the high-quality development of designated medical institutions through measures such as implementing prepayment of health insurance funds, shortening settlement cycles, strengthening information sharing, and optimizing management services.

Recently, the National Health Insurance Administration issued a notice to issue the “Model Medical Insurance Service Agreement for Designated Medical Institutions” and “Model Medical Insurance Service Agreement for Designated Retail Pharmacies”, which provide basic guidelines for all co-ordinated regions of the country to draw up new medical insurance service agreement texts. The 2026 model agreement further revised and perfected the 2024 model agreement, formulated and issued a negative list of agreement management, refined the specific circumstances, forms, and basis for handling the violations and violations of the agreement by designated medical institutions, clearly delineated the “bottom line” of the designated medical institutions' compliance with the law and regulations, and further strictly regulated management. At the same time, the 2026 model agreement emphasizes the principle of voluntary and equal consultation, empowers the development of designated pharmaceutical institutions, and helps the high-quality development of designated medical institutions through measures such as implementing prepayment of health insurance funds, shortening settlement cycles, strengthening information sharing, and optimizing management services.